# Ipamorelin Dosage in the Research: Doses Studied, Routes and Half-Life > Ipamorelin dosage as the studies recorded it — the human IV doses, the rodent subcutaneous regimens, the ~2-hour half-life and routes. Research context only, never advice. The doses administered in published studies — by species, route and duration — with no number ever offered as a human protocol. ## Read this first This page reports the ipamorelin dosage figures that appear in published studies, and nothing more. Every number below was administered to a specific species, by a specific route, in a specific experiment — it is a record of what researchers did, not a suggestion for what anyone should do. There is no approved human dose of ipamorelin, because it was never approved. The community protocols that pair it with CJC-1295 and quote microgram amounts have no controlled-trial basis in humans, and this digest will not invent one. What the literature can tell you cleanly is the half-life (how fast it clears), the routes that have been studied, and the doses used in the handful of real experiments. We give you those, in third person, with citations — and we leave the decision-making where it belongs, outside a research digest. ## Doses recorded in the studies In the human pharmacokinetic study, healthy men received single intravenous infusions of 4.21 to 140.45 nmol/kg over fifteen minutes [2]. In the human Phase 2 ileus trial, patients received 0.03 mg/kg intravenously twice daily for up to seven days [3]. In the rat bone-growth study, animals received 18, 90 or 450 micrograms per day subcutaneously, split three times daily, for fifteen days [4]. In the 2024 ferret cachexia study, ipamorelin was given at 1 to 3 mg/kg intraperitoneally [5]. These span vastly different species and goals; none translates to a human regimen, and the contrast between a microgram-per-day rat protocol and a milligram-per-kilogram ferret dose is itself a caution against casual extrapolation. ## Half-life and pharmacokinetics Ipamorelin's terminal half-life in healthy human volunteers is approximately two hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response it produces is a single discrete pulse peaking around forty minutes (0.67 h) after dosing, then subsiding [2]. The kinetics were dose-proportional across the tested range, meaning the body handled larger doses in a linear, predictable way [2]. This short half-life and single-pulse profile is exactly the pharmacology that the combination protocols try to lengthen by adding a long-acting GHRH analog. ## How much cjc-1295 ipamorelin should i take The honest answer to "how much cjc-1295 ipamorelin should i take" is that no published controlled trial establishes a human dose for the combination, so this digest does not provide one. The CJC-1295 human data that exist describe 30 to 60 micrograms per kilogram subcutaneously producing dose-dependent growth-hormone increases [11], but that is single-agent CJC-1295 pharmacology in a study, not a combination protocol and not a recommendation. Ipamorelin's own human exposure was characterized only intravenously [2][3]. The subcutaneous, paired, repeated-dose regimens circulated in communities are anecdotal and untested as a combination — described here as protocols people use, never as protocols this site endorses. ## How to reconstitute cjc-1295 ipamorelin 5mg On "how to reconstitute cjc-1295 ipamorelin 5mg": ipamorelin is supplied as a lyophilized (freeze-dried) powder, as free base or acetate salt, and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction, and this digest gives no step-by-step mixing protocol or injection guidance — that falls outside an editorial summary of the science. ## Routes that have been studied Ipamorelin has been studied intravenously (human pharmacokinetics and the clinical trial; rodent efficacy), subcutaneously (the rodent bone and body-composition studies, and the dominant route in community use), intraperitoneally (rodent and ferret efficacy work), and intranasally (rodent pharmacokinetics, with roughly 20 percent bioavailability) [2][4][5]. Oral dosing applies only to engineered ipamorelin-derived analogs, not to ipamorelin itself, which is not orally bioavailable [4]. The mismatch between the routes that were actually studied and the route most people use is one more reason the human safety picture is genuinely incomplete. ## Why study doses do not translate to a protocol It is tempting to read a study dose as a recipe, and it is a mistake. The human numbers come from intravenous infusions in a controlled setting — a 1999 pharmacokinetic study using doses up to 140.45 nmol/kg [2], and a clinical trial using 0.03 mg/kg twice daily for at most a week [3]. The animal numbers are scaled to the metabolism of rats and ferrets, not people, and even within the animal work the units jump from micrograms per day in a rat skeleton study [4] to milligrams per kilogram in a ferret cachexia study [5]. None of these establishes how a subcutaneously self-administered dose would behave in a person over weeks or months, because no study has measured that. A dose that produced a single growth-hormone pulse on an infusion pump tells you about pharmacology, not about a safe or effective regimen. ## Stability, handling and anti-doping detection As supplied, ipamorelin is a lyophilized powder kept dry and cold; once reconstituted it is treated like any peptide — refrigerated, shielded from heat and from repeated freeze-thaw, which degrade it [2]. These are general research-supply handling notes, not preparation instructions. One further fact belongs on any honest dosage page: ipamorelin is a growth-hormone secretagogue prohibited in sport at all times under the WADA list (category S2), and its class is detectable in urine by accredited anti-doping laboratories. Anyone subject to drug testing should treat the compound as detectable, regardless of dose or route. --- A vetted, combination-stacks-first reading of the ipamorelin record — the selective GH pulse and the CJC-1295 pairing examined in measured detail, ipamorelin's own studies kept distinct from its chemical relatives, and the popular protocols held to the trial that was never run on them; no clinic behind the name, no seller endorsed, and nothing here dosed, prescribed, or sold.